Ligand Pharmaceuticals (LGND) Preferred Stock Liabilities (2011 - 2012)

Ligand Pharmaceuticals (LGND) reported Preferred Stock Liabilities of $8.3 million for Q1 2012, down 0.53% sequentially from $8.3 million in Q4 2011.

Ligand Pharmaceuticals (LGND) Preferred Stock Liabilities (2011 - 2012) Analysis & Trends

Ligand Pharmaceuticals (LGND) has 2 years of Preferred Stock Liabilities data on file, last reported at $8.3 million in Q1 2012.

For the quarter ending Q1 2012, Preferred Stock Liabilities changed N/A year-over-year to $8.3 million; the trailing twelve-month figure through Mar 2012 stood at $8.3 million (changed N/A YoY), and the FY2011 full-year result was $8.3 million, changed N/A from the prior year.
Preferred Stock Liabilities eased to $8.3 million in Q1 2012, from $8.3 million in the prior quarter.
In the past five years, Preferred Stock Liabilities ranged from a high of $8.3 million in Q4 2011 to a low of $8.3 million in Q1 2012.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Stock Liabilities (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Ligand Pharmaceuticals	6.05 Bn	5.27 Bn	48.45 Mn	-

Download Data

Date	Value
Mar 31, 2012	8.30 Mn
Dec 31, 2011	8.34 Mn